CONCOMITANT TREATMENT WITH ALEGLITAZAR DOES NOT CHANGE THE EFFECTS ON RENAL FUNCTION INDUCED BY ASPIRIN

Authors :: F. Hoffmann-La Roche Ag
Dennis Ruff
Carolina Pellanda
Ruth Penn
Annette Sauter
Zainab Ansari
Thorsten Ruf
Source :: Journal of the American College of Cardiology. 59(13)
Publication Year :: 2012
Publisher :: Elsevier BV, 2012.
Abstract: Aleglitazar is a dual peroxisome proliferator-activated receptor a/? agonist in development for cardiovascular risk reduction in patients following an acute coronary syndrome (ACS) who have type 2 diabetes mellitus. Most ACS patients receive aspirin, which is associated with decreased glomerular

Full Text Access

Tools